Who we are

As an international association of research groups from Germany (Heidelberg), UK (Newcastle), Finland (Helsinki) and the Netherlands (Groningen) we initiated INDICATE in October 2019 at the meeting of European Hereditary Tumor Group (EHTG). Our goal is to analyze the potential of HLA type as cancer risk modulator in Lynch syndrome individuals and possibly to roll out the impact of HLA type on cancer risk in general population. We are happy to expand our team and involve new collaboration partners from all over the world, who wish to contribute to this research initiative.